Shares of Agilent Technologies surged 12% to $152.39 after the company confirmed it closed its $950 million all-cash purchase of Biocare Medical, a specialist in cancer tissue diagnostics. The deal, first announced in March, removes the last uncertainty hanging over a transaction that Wall Street had already been pricing as a strategic win. The question now: whether the premium investors are paying today can be justified by tomorrow's earnings.
A Cancer Diagnostics Deal That Tilts Agilent's Revenue Mix
Agilent acquired Biocare in an all-cash transaction valued at $950 million to enhance its pathology portfolio.
Biocare's products focus on diagnostic techniques for cancer patients, and the company has developed more than 300 specialized antibodies. Critically, Agilent said the deal is expected to support growth, margins, and non-instrument revenue mix — meaning more recurring revenue from consumables and reagents rather than one-time equipment sales. For a company that generated $6.95 billion in revenue during fiscal 2025 , Biocare's contribution is modest in size but strategically important in quality.
Earnings Boost Won't Arrive Overnight
Agilent expects the acquisition to be accretive to the company's top-line growth rate, margin profile, and non-instrument revenue mix in the first year, but anticipates the deal will become accretive to earnings per share approximately 12 months following the close. That gap matters: integration costs and deal-related expenses will weigh on profits near-term. The expected impact on Agilent's fiscal year 2026 financials will be provided as part of the company's third quarter earnings release — scheduled for August 18, 2026.
Agilent Took on New Debt to Pay for It
Agilent closed the sale of $600 million in aggregate principal amount of its 4.900% Senior Notes due 2032 just days before completing the deal, signaling that a significant portion of the purchase price was debt-financed. At 4.9% interest, that's a meaningful carrying cost that needs to be offset by Biocare's cash flows.
The Stock Is Now Testing Analyst Targets
At $152.39, Agilent is closing in on the average 12-month analyst price target of $160.35 . The stock has already rallied roughly 20% from its 52-week low of $108.35. Q2 2026 revenue hit $1.83 billion, up 10% year-over-year, and EPS of $1.49 exceeded forecasts by $0.07. Momentum is real, but today's price now bakes in much of the good news — leaving less room for error when the August earnings call details actual integration costs and Biocare's contribution.